Biovest International, Inc. (BVTI.OB) Reports Clinically and Statistically Significant Data from Phase 3 Trial of BiovaxID®
Biovest International, Inc. (BVTI.OB), a pioneer in the development of advanced individualized immunotherapies for life-threatening cancers of the blood system, and a majority-owned subsidiary of Accentia Biopharmaceuticals, Inc. (NASDAQ:ABPI), recently announced clinically and statistically significant unblinded data from the company’s randomized controlled pivotal Phase 3 fast-tracked clinical trial of BiovaxID®, a treatment for non-Hodgkin’s lymphoma. BiovaxID® is a personalized, patient-specific therapeutic vaccine designed to stimulate the patient’s own immune system to recognize and destroy cancerous B-cells that may remain in the body after chemotherapy treatment. BiovaxID® is designed to kill only cancerous B-cells for patients diagnosed with non-Hodgkin’s lymphoma, unlike…